Polivy Market Report 2026

Polivy Market Overview

• The Polivy market growth in the historic period has been driven by increasing incidence of diffuse large b-cell lymphoma, advancements in monoclonal antibody development • Market expansion is supported by increasing demand for personalized oncology drugs, rising investments in adc research pipelines • Growth Driver: Growing Incidence Of Diffuse Large B-Cell Lymphoma Boosts Demand For Polivy • Market Trend: Adoption of First-Line Antibody-Drug Conjugate Combinations in Polivy Market to Improve DLBCL Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

The key promising market opportunities in the polivy market include: • Previously Untreated Diffuse Large B-Cell Lymphoma (Segmentation By By Indication) → Expected gain of $1.69 Billion • Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Segmentation By By Indication) → Expected gain of $1.24 Billion

What Is Covered Under Polivy Market?

Polivy (polatuzumab vedotin) is an antibody-drug conjugate used for the treatment of diffuse large B-cell lymphoma, which is a type of non-Hodgkin lymphoma. It is specifically indicated for adult patients with relapsed or refractory diffuse large B-cell lymphoma after they have undergone at least two prior therapies. Additionally, it can be used as a first-line treatment in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone for patients with moderate- to high-risk diffuse large B-cell lymphoma. The main indications of polivy are previously untreated diffuse large b-cell lymphoma, relapsed or refractory diffuse large b-cell lymphoma. Previously untreated diffuse large B-cell lymphoma is a form of cancer affecting white blood cells that have not received any prior treatment. It is typically aggressive and requires prompt medical intervention. Polivy is used as part of combination therapy to address this condition effectively. It is dose in the form of injectable solutions and distributed through various channels such as direct sales, pharmaceutical wholesalers, and online pharmacies.

What Is The Polivy Market Growth Forecast?

The growth in the forecast period can be attributed to increasing demand for personalized oncology drugs, rising investments in adc research pipelines, expansion of first-line combination therapies, growing focus on treatment-resistant lymphomas, increasing regulatory approvals for targeted biologics. Major trends in the forecast period include increasing adoption of antibody-drug conjugates, rising use in targeted lymphoma therapies, growing integration with combination chemotherapy regimens, expansion of precision oncology treatments, enhanced focus on cd79b-targeted drugs.

What Are The Drivers Of The Polivy Market?

The increasing incidence of diffuse large B-cell lymphoma is expected to propel the growth of the polivy market going forward. Diffuse large B-cell lymphoma (DLBCL), the most prevalent type of non-hodgkin lymphoma (NHL), is classified as a highly aggressive blood cancer that originates from B-lymphocytes, which are white blood cells essential for the immune system's function of producing antibodies to combat infections. The increasing incidence of diffuse large B-cell lymphoma can be attributed to several factors, including an aging population, rising rates of immunosuppression due to conditions such as HIV/AIDS and organ transplants, and environmental exposures that contribute to the disease's etiology. Polivy is used in combination with chemotherapy to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in patients who have received prior treatments. For instance, in July 2024, according to a report published by the Royal College of Pathologists, a UK-based professional membership organization, each year in the UK, approximately 5,500 individuals are diagnosed with diffuse large B-cell lymphoma (DLBCL), which is a highly aggressive form of non-Hodgkin lymphoma. About 30% of these patients will experience refractory disease or relapse shortly after their initial treatment. Therefore, the increasing incidence of diffuse large B-cell lymphoma is driving the growth of the polivy industry. The rising number of oncology procedures is expected to propel the growth of the polivy market going forward. Oncology procedures refer to medical tests, treatments, and interventions performed to diagnose, manage, and treat various types of cancer. Oncology procedures are increasing as more healthcare providers and patients prioritize early cancer detection and access to effective targeted therapies. Polivy plays a crucial role in the rising number of oncology procedures by offering targeted therapy that improves outcomes and expands treatment options for cancer patients. For instance, in February 2024, according to the World Health Organization, a US-based United Nations agency, reported that over 35 million new cancer cases are predicted in 2050, a 77% increase from the estimated 20 million cases in 2022. Therefore, the rising number of oncology procedures is driving the growth of the polivy industry.

How Will The Drivers Impact Growth In The Global Polivy Market?

• Expansion of Indications and Broader Clinical Adoption in Diffuse Large B-Cell Lymphoma (High) – During the forecast period, the expansion of indications and broader clinical adoption in diffuse large B-cell lymphoma is expected to become a key growth driver for the polivy market by 2030. Expanding clinical utilization across treatment settings is increasing physician confidence in targeted lymphoma therapies and strengthening incorporation into evolving oncology protocols. Broader application across patient populations is improving treatment accessibility while supporting earlier therapeutic intervention strategies. Healthcare systems are also prioritizing advanced biologic treatment approaches that improve disease management outcomes and optimize therapeutic effectiveness. This expansion of clinical adoption is strengthening long-term commercial growth potential. • Rising Global Incidence of Hematological Malignancies (Medium) – During the forecast period, the rising global incidence of hematological malignancies is expected to emerge as a major factor driving the expansion of the polivy market by 2030. Increasing diagnosis rates of blood cancers are creating greater demand for advanced targeted treatment solutions capable of improving patient outcomes. Aging populations and improved disease detection capabilities are contributing to expanding treatment volumes across healthcare systems globally. Growing awareness regarding hematologic cancer management is further supporting adoption of innovative oncology therapeutics. • Increasing Preference for Antibody-Drug Conjugate (ADC) Therapies (Low) – During the forecast period, the increasing preference for antibody-drug conjugate (ADC) therapies is expected to act as a key growth catalyst for the polivy market by 2030. Precision-targeted oncology therapies are gaining strong acceptance due to their ability to selectively deliver treatment while minimizing broader systemic exposure. Advancements in biologic engineering technologies are strengthening therapeutic performance and encouraging wider integration into cancer treatment strategies. Healthcare providers are increasingly adopting next-generation targeted therapies to improve clinical efficiency and long-term disease management approaches. As antibody-drug conjugate utilization expands globally, demand for innovative oncology biologics is expected to accelerate.

How Will The Restraints Impact Growth In The Global Polivy Market?

• High Treatment Costs and Reimbursement Challenges (High) – During the forecast period, the premium pricing associated with advanced biologic oncology therapies creates affordability concerns across healthcare systems, particularly in cost-sensitive markets. Reimbursement limitations, payer scrutiny regarding treatment economics, and budget pressures within hospitals may restrict widespread adoption. These pricing-related barriers could slow market expansion despite strong clinical demand fundamentals. (-21%) • Competitive Pressure from Emerging Lymphoma Therapies (Medium) – During the forecast period, the lymphoma treatment landscape is becoming increasingly competitive with the introduction of newer targeted therapies, CAR-T cell treatments, biosimilar developments, and next-generation antibody-drug conjugates. Competitive innovation can reduce prescribing concentration toward Polivy and create pricing pressure over time. Expanding therapeutic alternatives may moderate market growth potential during the forecast period. (-18%) • Safety Concerns and Management of Treatment-Related Adverse Events (Low) – During the forecast period, the safety concerns associated with treatment-related adverse events are expected to restrain the growth of the Polivy market. While Polivy has demonstrated strong efficacy in certain lymphoma indications, its use can be associated with adverse effects such as peripheral neuropathy, infections, hematologic toxicities, and infusion-related reactions. These risks may require dose modifications, treatment interruptions, or additional supportive care measures, increasing the complexity of patient management. Physicians may exercise caution when prescribing the therapy to elderly patients or those with significant comorbidities. As a result, safety-related considerations can limit treatment uptake and act as a barrier to broader market adoption.

Key Players In The Global Polivy Market

Major companies operating in the polivy market are F. Hoffmann-La Roche Ltd (Genentech Inc.)

Global Polivy Market Trends and Insights

Major companies operating in the polivy market are focusing on developing innovative regimens, such as first-line antibody-drug conjugate (ADC) combinations, to better target aggressive B-cell lymphomas and improve patient outcomes. A first-line ADC combination integrates a monoclonal antibody that selectively binds to tumor-specific proteins with a cytotoxic payload, enabling highly targeted therapy, unlike conventional chemotherapy, which affects both cancerous and healthy cells. For instance, in April 2023, Genentech, a U.S.-based biotechnology company, received FDA approval for Polivy (polatuzumab vedotin-piiq) in combination with R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) for previously untreated diffuse large B-cell lymphoma (DLBCL) in adults. Polivy is a first-in-class anti-CD79b ADC developed using Seagen’s linker-payload technology: the antibody targets the CD79b protein on B-cells, the conjugated payload (vedotin) is a potent microtubule-disrupting agent, and upon binding the drug is internalized into the cancer cell where the cytotoxic agent is released to induce cell death. Its unique features include high specificity toward malignant B-cells, a more favorable safety profile compared to systemic chemotherapy, and a demonstrated 27% reduction in risk of progression or death versus standard R-CHOP in the pivotal POLARIX study. This combination is now poised to transform first-line treatment in DLBCL, potentially reducing relapse rates and alleviating long-term patient burden.

What Defines the Polivy Market?

The polivy market consists of sales of polivy (polatuzumab vedotin) injections in 30 mg and 140 mg vials. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Polivy Market Report 2026?

The polivy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the polivy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.